These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26839889)

  • 1. Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections.
    Li FF; Fu LY; Zhang WL; Su XF; Wu JD; Sun J; Ye L; Ma JH
    J Diabetes Res; 2016; 2016():1028945. PubMed ID: 26839889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
    Dieuzeide G; Chuang LM; Almaghamsi A; Zilov A; Chen JW; Lavalle-González FJ
    Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
    Xu S; Liu X; Ming J; Ji Q
    Trials; 2016 Mar; 17():160. PubMed ID: 27009108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
    Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
    Wan H; Zhao D; Shen J; Lu L; Zhang T; Chen Z
    J Diabetes Res; 2016; 2016():9849328. PubMed ID: 26798658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
    Malek R; Arbouche Z; Bachaoui M; Zinai S; Dahaoui A; Senoussaoui S; Salah-Mansour A
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S45-9. PubMed ID: 23958572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of prednisolone-induced hyperglycaemia in hospitalized patients: Insights from a randomized, controlled study.
    Radhakutty A; Stranks JL; Mangelsdorf BL; Drake SM; Roberts GW; Zimmermann AT; Stranks SN; Thompson CH; Burt MG
    Diabetes Obes Metab; 2017 Apr; 19(4):571-578. PubMed ID: 27995731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.
    Chen L; Xing X; Lei M; Liu J; Shi Y; Li P; Qin G; Li C; Li Y; Wang Q; Gao T; Hu L; Wang Y; Yang W
    Chin Med J (Engl); 2014; 127(2):208-12. PubMed ID: 24438605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.
    Su K; Lv C; Ji Z; Wang Y; Wang H; Bai Y; Liu Y
    Am J Ther; 2018; 25(6):e609-e616. PubMed ID: 26844723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
    Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Qureshi MS; Shaikh MZ
    J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK; Schmüser C; Askonen K; Saukkonen T
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
    Hirsch IB; Bode BW; Garg S; Lane WS; Sussman A; Hu P; Santiago OM; Kolaczynski JW;
    Diabetes Care; 2005 Mar; 28(3):533-8. PubMed ID: 15735183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care.
    Kostev K; Dippel FW; Rathmann W
    Prim Care Diabetes; 2016 Apr; 10(2):142-7. PubMed ID: 26324105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentre randomized controlled trial with sensor-augmented pump vs multiple daily injections in hospitalized patients with type 2 diabetes in China: Time to reach target glucose.
    Gu W; Liu Y; Chen Y; Deng W; Ran X; Chen L; Zhu D; Yang J; Shin J; Lee SW; Cordero TL; Mu Y
    Diabetes Metab; 2017 Sep; 43(4):359-363. PubMed ID: 28236571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous Glucose Monitoring in Newly Diagnosed Type 2 Diabetes Patients Reveals a Potential Risk of Hypoglycemia in Older Men.
    Li FF; Liu BL; Zhu HH; Li T; Zhang WL; Su XF; Wu JD; Wang XQ; Xu N; Yu WN; Yuan Q; Qi GC; Ye L; Lee KO; Ma JH
    J Diabetes Res; 2017; 2017():2740372. PubMed ID: 28271075
    [No Abstract]   [Full Text] [Related]  

  • 18. Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment.
    Zeng L; Lu H; Deng H; Mu P; Li X; Wang M
    Diabetes Technol Ther; 2012 Jan; 14(1):35-42. PubMed ID: 21877913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of continuous subcutaneous insulin infusion and multiple daily insulin injections in Chinese patients with type 2 diabetes mellitus.
    Yang H; Heng X; Liang C; Liu X; Du W; Li S; Wang Y; Dong Q; Li W; Pan Z; Gong Q; Gao G
    J Int Med Res; 2014 Aug; 42(4):1002-10. PubMed ID: 24965335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.